Key Points
-
Chimeric antigen receptor (CAR)-T-cell therapy has shown enormous promise in the treatment of B-cell acute lymphoblastic leukaemia; at present, CD19-targeted CAR-T-cell-based treatment of other B-cell malignancies is less effective
-
Other targets for CAR-T-cell therapy of haematological malignancies that are undergoing clinical testing include CD20, CD22, ROR1, IgΚ, BCMA, CD138, CD33, CD123 and LewisY antigen
-
Targets for CAR-T-cell therapy of solid malignancies currently being tested in the clinic include PSMA, FAP, CEA, CD171, GD2, glypican-3, HER2 and IL-13Rα
-
Several strategies are under development to improve CAR-T-cell-mediated antitumour responses; these include, among others, 'armoured' CAR T cells, dual receptor/cytokine-based CARs, CARs based on natural-killer-cell receptors and other cell receptors
-
Strategies to improve the safety of CAR-T-cell therapy involve improved management of cytokine-release syndrome, as well as engineered CAR T cells that are easier to eradicate in case of adverse events
Abstract
The engineered expression of chimeric antigen receptors (CARs) on the surface of T cells enables the redirection of T-cell specificity. Early clinical trials using CAR T cells for the treatment of patients with cancer showed modest results, but the impressive outcomes of several trials of CD19-targeted CAR T cells in the treatment of patients with B-cell malignancies have generated an increased enthusiasm for this approach. Important lessons have been derived from clinical trials of CD19-specific CAR T cells, and ongoing clinical trials are testing CAR designs directed at novel targets involved in haematological and solid malignancies. In this Review, we discuss these trials and present strategies that can increase the antitumour efficacy and safety of CAR T-cell therapy. Given the fast-moving nature of this field, we only discuss studies with direct translational application currently or soon-to-be tested in the clinical setting.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra138 (2013).
Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517–528 (2015).
Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
Jensen, M. C. et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol. Blood Marrow Transplant. 16, 1245–1256 (2010).
Lamers, C. H. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20–e22 (2006).
Till, B. G. et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112, 2261–2271 (2008).
Savoldo, B. et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822–1826 (2011).
Scholler, J. et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 4, 132ra153 (2012).
Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517–528 (2014).
Carpenito, C. et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl Acad. Sci. USA 106, 3360–3365 (2009).
Zhong, X. S., Matsushita, M., Plotkin, J., Riviere, I. & Sadelain, M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 18, 413–420 (2010).
US National Library of Science. ClinicalTrials.gov[online], (2015).
US National Library of Science. ClinicalTrials.gov[online], (2016).
Park, J. H. et al. Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL [abstract]. J. Clin. Oncol. 33 (Suppl.), 7010 (2015).
US National Library of Science. ClinicalTrials.gov[online], (2016).
Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509–1518 (2013).
US National Library of Science. ClinicalTrials.gov[online], (2015).
US National Library of Science. ClinicalTrials.gov [online],[online], (2015).
Sommermeyer, D. et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30, 492–500 (2015).
Turtle, C. J. et al. Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition [abstract]. J. Clin. Oncol. 33 (Suppl.), 3006 (2015).
Brentjens, R. J. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817–4828 (2011).
Kochenderfer, J. N. et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709–2720 (2012).
Porter, D. L. et al. Randomized, phase II dose optimization study of chimeric antigen receptor modified t cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL. Presented at the 55th ASH Annual Meeting and Exposition (2014).
Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).
Kochenderfer, J. N. et al. Anti-CD19 CAR T cells administered after low-dose chemotherapy can induce remissions of chemotherapy-refractory diffuse large B-cell lymphoma. Blood 124, 550 (2014).
Schuster, S. J. et al. Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas [abstract]. Blood 124 (Suppl.), 3087 (2014).
US National Library of Science. ClinicalTrials.gov[online], (2015).
Sauter, C. S. et al. Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL) [abstract]. J. Clin. Oncol. 33 (Suppl.), 8515 (2015).
Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra225 (2014).
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).
US National Library of Science. ClinicalTrials.gov[online], (2015).
Garfall, A. L. et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N. Engl. J. Med. 373, 1040–1047 (2015).
Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1282–1295 (2015).
US National Library of Science. ClinicalTrials.gov[online], (2015).
US National Library of Science. ClinicalTrials.gov[online], (2014).
US National Library of Science. ClinicalTrials.gov[online], (2015).
US National Library of Science. ClinicalTrials.gov[online], (2016).
US National Library of Science. ClinicalTrials.gov[online], (2015).
US National Library of Science. ClinicalTrials.gov[online], (2016).
US National Library of Science. ClinicalTrials.gov[online], (2016).
US National Library of Science. ClinicalTrials.gov[online], (2016).
US National Library of Science. ClinicalTrials.gov[online], (2012).
Nitschke, L. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol. Rev. 230, 128–143 (2009).
Dotti, G., Gottschalk, S., Savoldo, B. & Brenner, M. K. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol. Rev. 257, 107–126 (2014).
Haso, W. et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121, 1165–1174 (2013).
Till, B. G. et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119, 3940–3950 (2012).
US National Library of Science. ClinicalTrials.gov[online], (2015).
Wang, Y. et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin. Immunol. 155, 160–175 (2014).
Zhang, S. et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am. J. Pathol. 181, 1903–1910 (2012).
Al-Shawi, R., Ashton, S. V., Underwood, C. & Simons, J. P. Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development. Dev. Genes Evol. 211, 161–171 (2001).
Hudecek, M. et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 116, 4532–4541 (2010).
Vera, J. et al. T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 108, 3890–3897 (2006).
Deniger, D. C. et al. Sleeping Beauty transposition of chimeric antigen receptors targeting receptor tyrosine kinase-like orphan receptor-1 (ROR1) into diverse memory T-cell populations. PLoS ONE 10, e0128151 (2015).
Ellis, T. M., Simms, P. E., Slivnick, D. J., Jack, H. M. & Fisher, R. I. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J. Immunol. 151, 2380–2389 (1993).
Hombach, A. et al. An anti-CD30 chimeric receptor that mediates CD3-ζ-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. Cancer Res. 58, 1116–1119 (1998).
US National Library of Science. ClinicalTrials.gov[online], (2016).
US National Library of Science. ClinicalTrials.gov[online], (2016).
Zhang, H. et al. Differential expression of syndecan-1 mediates cationic nanoparticle toxicity in undifferentiated versus differentiated normal human bronchial epithelial cells. ACS Nano 5, 2756–2769 (2011).
Guo, B. et al. CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma. J. Cell. Immunother. http://dx.doi.org/10.1016/j.jocit.2014.11.001 (2015).
Carpenter, R. O. et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19, 2048–2060 (2013).
Feldman, E. et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia 17, 314–318 (2003).
Roberts, A. W. et al. A phase I study of anti-CD123 monoclonal antibody (mAb) CSL360 targeting leukemia stem cells (LSC) in AML [abstract]. J. Clin. Oncol. 28 (Suppl.), e13012 (2010).
Mardiros, A. et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 122, 3138–3148 (2013).
Shi, J. et al. Identification of CD123+ myeloid dendritic cells as an early-stage immature subset with strong tumoristatic potential. Cancer Lett. 270, 19–29 (2008).
Tettamanti, S. et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br. J. Haematol. 161, 389–401 (2013).
Sievers, E. L. et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19, 3244–3254 (2001).
Hoyer, J. D., Grogg, K. L., Hanson, C. A., Gamez, J. D. & Dogan, A. CD33 detection by immunohistochemistry in paraffin-embedded tissues: a new antibody shows excellent specificity and sensitivity for cells of myelomonocytic lineage. Am. J. Clin. Pathol. 129, 316–323 (2008).
Wang, Q. S. et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol. Ther. 23, 184–191 (2015).
Kobayashi, K. et al. Lewis blood group-related antigen expression in normal gastric epithelium, intestinal metaplasia, gastric adenoma, and gastric carcinoma. Am. J. Gastroenterol. 88, 919–924 (1993).
Peinert, S. et al. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther. 17, 678–686 (2010).
Schuessler, M. H. et al. Blood group and blood-group-related antigens in normal pancreas and pancreas cancer: enhanced expression of precursor type 1, Tn and sialyl-Tn in pancreas cancer. Int. J. Cancer 47, 180–187 (1991).
Ritchie, D. S. et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol. Ther. 21, 2122–2129 (2013).
Chang, S. S. Overview of prostate-specific membrane antigen. Rev. Urol. 6, S13–S18 (2004).
Haffner, M. C. et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum. Pathol. 40, 1754–1761 (2009).
Maher, J., Brentjens, R. J., Gunset, G., Riviere, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat. Biotechnol. 20, 70–75 (2002).
US National Library of Science. ClinicalTrials.gov[online], (2015).
Slovin, S. F. et al. Targeting castration resistant prostate cancer (CRPC) with autologous PSMA-directed CAR+ T cells. J. Clin. Oncol. 30, TPS4700 (2012).
US National Library of Science. ClinicalTrials.gov[online], (2014).
Junghans, R. P. et al. Abstract C13: phase I trial of anti-PSMA designer T cells in advanced prostate cancer. Cancer Res. 72, C13 (2012).
Hassan, R. & Ho, M. Mesothelin targeted cancer immunotherapy. Eur. J. Cancer 44, 46–53 (2008).
US National Library of Science. ClinicalTrials.gov[online], (2015).
Beatty, G. L. et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol. Res. 2, 112–120 (2014).
Maus, M. V. et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res. 1, 26–31 (2013).
US National Library of Science. ClinicalTrials.gov[online], (2016).
US National Library of Science. ClinicalTrials.gov[online], (2015).
US National Library of Science. ClinicalTrials.gov[online], (2015).
Mathew, S. et al. The gene for fibroblast activation protein α (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23. Genomics 25, 335–337 (1995).
Petrausch, U. et al. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). BMC Cancer 12, 615 (2012).
Schuberth, P. C. et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J. Transl. Med. 11, 187 (2013).
US National Library of Science. ClinicalTrials.gov[online], (2016).
Arteaga, C. L. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7 (Suppl. 4), 31–39 (2002).
Feldkamp, M. M., Lala, P., Lau, N., Roncari, L. & Guha, A. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 45, 1442–1453 (1999).
Thomas, M. Cetuximab: adverse event profile and recommendations for toxicity management. Clin. J. Oncol. Nurs. 9, 332–338 (2005).
Johnson, L. A. et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci. Transl. Med. 7, 275ra222 (2015).
US National Library of Science. ClinicalTrials.gov[online], (2016).
Morgan, R. A. et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum. Gene Ther. 23, 1043–1053 (2012).
US National Library of Science. ClinicalTrials.gov[online], (2016).
US National Library of Science. ClinicalTrials.gov[online], (2015).
Hammarstrom, S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin. Cancer Biol. 9, 67–81 (1999).
US National Library of Science. ClinicalTrials.gov[online], (2015).
Parkhurst, M. R. et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620–626 (2011).
Katz, S. C. et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin. Cancer Res. 21, 3149–3159 (2015).
US National Library of Science. ClinicalTrials.gov[online], (2015).
Huszar, M. et al. Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum. Pathol. 37, 1000–1008 (2006).
Meli, M. L. et al. Anti-neuroblastoma antibody chCE7 binds to an isoform of L1-CAM present in renal carcinoma cells. Int. J. Cancer 83, 401–408 (1999).
US National Library of Science. ClinicalTrials.gov[online], (2014).
Hong, H. et al. Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes. J. Immunother. 37, 93–104 (2014).
Suzuki, M. & Cheung, N. K. Disialoganglioside GD2 as a therapeutic target for human diseases. Expert Opin. Ther. Targets 19, 349–362 (2015).
Zhang, S. et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int. J. Cancer 73, 42–49 (1997).
Louis, C. U. et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050–6056 (2011).
US National Library of Science. ClinicalTrials.gov[online], (2015).
US National Library of Science. ClinicalTrials.gov[online], (2016).
Gargett, T. & Brown, M. P. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2. Cytotherapy 17, 487–495 (2015).
US National Library of Science. ClinicalTrials.gov[online], (2015).
US National Library of Science. ClinicalTrials.gov[online], (2015).
Baumhoer, D. et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am. J. Clin. Pathol. 129, 899–906 (2008).
US National Library of Science. ClinicalTrials.gov[online], (2015).
Press, M. F., Cordon-Cardo, C. & Slamon, D. J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5, 953–962 (1990).
Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989).
US National Library of Science. ClinicalTrials.gov[online], (2015).
Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843–851 (2010).
US National Library of Science. ClinicalTrials.gov[online], (2015).
Ahmed, N. et al. Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J. Clin. Oncol. 33, 1688–1696 (2015).
Ahmed, N. et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol. Ther. 17, 1779–1787 (2009).
Zhao, Y. et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 183, 5563–5574 (2009).
US National Library of Science. ClinicalTrials.gov[online], (2016).
US National Library of Science. ClinicalTrials.gov[online], (2016).
Debinski, W., Gibo, D. M., Hulet, S. W., Connor, J. R. & Gillespie, G. Y. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin. Cancer Res. 5, 985–990 (1999).
US National Library of Science. ClinicalTrials.gov[online], (2011).
Brown, C. E. et al. Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin. Cancer Res. 21, 4062–4072 (2015).
US National Library of Science. ClinicalTrials.gov[online], (2015).
Chinnasamy, D. et al. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin. Cancer Res. 18, 1672–1683 (2012).
Chmielewski, M., Kopecky, C., Hombach, A. A. & Abken, H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71, 5697–5706 (2011).
Kerkar, S. P. et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 121, 4746–4757 (2011).
Pegram, H. J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133–4141 (2012).
Zhang, L. et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin. Cancer Res. 21, 2278–2288 (2015).
US National Library of Science. ClinicalTrials.gov[online], (2015).
Chekmasova, A. A. et al. Successful eradication of established peritoneal ovarian tumors in SCID-beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin. Cancer Res. 16, 3594–3606 (2010).
Koneru, M., O'Cearbhaill, R., Pendharkar, S., Spriggs, D. R. & Brentjens, R. J. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer. J. Transl. Med. 13, 102 (2015).
Yin, B. W. & Lloyd, K. O. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J. Biol. Chem. 276, 27371–27375 (2001).
Wilkie, S. et al. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J. Biol. Chem. 285, 25538–25544 (2010).
Davies, D. M. et al. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol. Med. 18, 565–576 (2012).
van Schalkwyk, M. C. et al. Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Hum. Gene Ther. Clin. Dev. 24, 134–142 (2013).
Zhang, J., Basher, F. & Wu, J. D. NKG2D ligands in tumor immunity: two sides of a coin. Front. Immunol. 6, 97 (2015).
Spear, P., Barber, A., Rynda-Apple, A. & Sentman, C. L. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunol. Cell Biol. 91, 435–440 (2013).
Sentman, C. L. & Meehan, K. R. NKG2D CARs as cell therapy for cancer. Cancer J. 20, 156–159 (2014).
Zhang, T., Barber, A. & Sentman, C. L. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Res. 67, 11029–11036 (2007).
US National Library of Science. ClinicalTrials.gov[online], (2016).
Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).
Choudhury, N. & Nakamura, Y. The importance of immunopharmacogenomics in cancer treatment: patient selection and monitoring for immune checkpoint antibodies. Cancer Sci 107, 107–115 (2015).
John, L. B. et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 19, 5636–5646 (2013).
US National Library of Science. ClinicalTrials.gov[online], (2015).
Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106–6115 (2006).
US National Library of Science. ClinicalTrials.gov[online], (2016).
Chen, J. C., Chang, Y. W., Hong, C. C., Yu, Y. H. & Su, J. L. The role of the VEGF-C/VEGFRs axis in tumor progression and therapy. Int. J. Mol. Sci. 14, 88–107 (2012).
Fukumura, D. et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94, 715–725 (1998).
Chinnasamy, D. et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J. Clin. Invest. 120, 3953–3968 (2010).
US National Library of Science. ClinicalTrials.gov[online], (2015).
Kochenderfer, J. N. et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540–549 (2015).
Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673–1683 (2011).
Wang, X. et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255–1263 (2011).
US National Library of Science. ClinicalTrials.gov[online], (2015).
Acknowledgements
R.J.B. receives financial support from The Annual Terry Fox Run for Cancer Research (New York) organized by the Canada Club of New York, Carson Family Charitable Trust, Kate's Team, Emerald Foundation, the Experimental Therapeutics Center of Memorial Sloan Kettering Cancer Center (Innovations in the structures, functions and targets of monoclonal antibody-based drugs for cancer), The Leukemia & Lymphoma society, The National Institutes of Health Grants (R01CA138738-05, PO1CA059350, PO1CA190174-01) and the William Lawrence and Blanche Hughes Foundation.
Author information
Authors and Affiliations
Contributions
H.J.J., S.R. and R.J.B. researched data for the article, contributed to discussing the article's content, wrote, reviewed and edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
H.J.J. and S.R. declare no competing interests. R.J.B. is a co-founder, stockholder and consultant for Juno Therapeutics Inc.
Rights and permissions
About this article
Cite this article
Jackson, H., Rafiq, S. & Brentjens, R. Driving CAR T-cells forward. Nat Rev Clin Oncol 13, 370–383 (2016). https://doi.org/10.1038/nrclinonc.2016.36
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2016.36
This article is cited by
-
Acellular scaffold-based approach for in situ genetic engineering of host T-cells in solid tumor immunotherapy
Military Medical Research (2024)
-
Unlocking the ‘ova’-coming power: immunotherapy’s role in shaping the future of ovarian cancer treatment
Medical Oncology (2024)
-
Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling
Nature Cancer (2024)
-
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Experimental Hematology & Oncology (2023)
-
CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma
Journal of Translational Medicine (2023)